Clinical Findings, Pathology, and Outcomes of C3GN after Kidney Transplantation

Overview of attention for article published in Journal of the American Society of Nephrology, December 2013

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#44 of 7,247)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 42 news outlets
twitter: 12 X users

f1000: 1 research highlight platform
guideline: 1 clinical guideline source

Readers on

mendeley: 102 Mendeley

So far, Altmetric has seen 51 news stories from 42 outlets.

6 Types of Treatment for Complement 3 Glomerulopathy

Verywell Health, 19 Jan 2026

Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

BioSpace, 08 Aug 2024

Met the primary endpoint, achieving statistically significant 68% (p

Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

USA Life Sciences Database, 08 Aug 2024

Met the primary endpoint, achieving statistically significant 68% (p

Apellis

Drug Development & Delivery, 08 Aug 2024

Apellis Pharmaceuticals, Inc. recently announced positive topline results from the Phase 3 VALIANT study investigating systemic…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 47 additional news stories.